Novel Blood Test Improves Detection of High-Grade Prostate Cancer
IsoPSA can correctly rule out high-grade prostate cancer 93% of the time and thus has the potential to reduce the number of unnecessary prostate biopsies.
Prostate And Other Male Cancers
Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed
Investigators suggest PSA testing frequencies based on post-operative baseline PSA.
Gleason 4+3 vs 3+4 PCa Tied To Higher Risk of Metastasis at Diagnosis
Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.
Single PSA Screening Has No Effect on Prostate Cancer Mortality
Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.
State Variation in PSA Screening After the 2011-2012 USPSTF Update
Not only is there immense state-by-state heterogeneity in PSA screening, but there is also marked variation within each state.
Early Prostate Cancer Salvage ADT Therapy Better
Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.
Proximal PSA Predicts Prostate Cancer Metastasis Risk
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
PSA Testing in Controls of Screening Trial May Undermine Results
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
Low-PSA, High-Grade Prostate Cancer Especially Lethal
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
- Loading...
Loading...
Loading... 
Loading...